Article Text

Download PDFPDF
Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage

Statistics from


  • Contributors KFX: planning, writing and being responsible for the overall content. XT and YY: collecting materials. HZ: writing.

  • Funding The National Natural Science Foundation of China (81570061), the National Key Research and Development Program of China (2016YFC0901502, 2016YFC0905101) and Beijing Municipal Science and Technology Project (Z151100003915126).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles